Neos Therapeutics Inc. (NEOS) Plunges 5.27% on January 13

Equities Staff  |

Neos Therapeutics Inc. (NEOS) had a rough trading day for Wednesday January 13 as shares tumbled 5.27%, or a loss of $-0.0431 per share, to close at $0.78. After opening the day at $0.79, shares of Neos Therapeutics Inc. traded as high as $0.85 and as low as $0.77. Volume was 5.38 million shares over 8,506 trades, against an average daily volume of n/a shares and a total float of 49.76 million.

As a result of the decline, Neos Therapeutics Inc. now has a market cap of $38.56 million. In the last year, shares of Neos Therapeutics Inc. have traded between a range of $1.99 and $0.46, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

For a complete fundamental analysis of Neos Therapeutics Inc., check out’s Stock Valuation Analysis report for NEOS.

Still paying commissions on stock trades? now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.

Neos Therapeutics Inc. is based out of Grand Prairie, TX and has some 213 employees. Its CEO is Gerald McLaughlin.

Neos Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Neos Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: NEOS’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change